{{Distinguish|Guanine|Guanosine|Guanidine|Guaifenesin|Clonidine}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 461124228
| IUPAC_name = ''N''-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
| image = Guanfacine.svg
| image2 = Guanfacine molecule ball.png
<!--Clinical data-->
| tradename = Afken, Estulic, Intuniv, Tenex
| Drugs.com = {{drugs.com|monograph|guanfacine}}
| licence_US = Guanfacine
| MedlinePlus = a601059
| DailyMedID = 9fc0bdc2-5ba2-48dd-aa87-7b0050a2d6ce
| pregnancy_US = B
| legal_US = Rx-only
| routes_of_administration = oral, [[intravenous]]
<!--Pharmacokinetic data-->
| bioavailability = 80-100% (IR), 58% (XR)<ref name = DM>{{cite web|title=Guanfacine (guanfacine) Tablet [Genpharm Inc.]|work=DailyMed|publisher=Genpharm Inc.|date=March 2007|accessdate=9 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9fc0bdc2-5ba2-48dd-aa87-7b0050a2d6ce}}</ref><ref name = MSR>{{cite web|title=guanfacine (Rx) - Intuniv, Tenex|work=Medscape Reference|publisher=WebMD|accessdate=9 November 2013|url=http://reference.medscape.com/drug/intuniv-tenex-guanfacine-342384}}</ref>
| protein_bound =  70%<ref name = DM/><ref name = MSR/>
| metabolism = [[CYP3A4]]<ref name = DM/><ref name = MSR/>
| elimination_half-life = IR: 10-17 hours; XR: 17 hours (10-30) in adults & adolescents and 14 hours in [[Paediatrics]]<ref name = DM/><ref name = MSR/><ref>{{cite journal|last1=Hofer|first1=Kristi N.|last2=Buck|first2=Marcia L.|title=New Treatment Options for Attention-Deficit/Hyperactivity Disorder (ADHD): Part II. Guanfacine|journal=Pediatric Pharmacotherapy|date=2008|issue=14|page=4|url=http://medscape.com/viewarticle/578747_4|publisher=Medscape}}</ref><ref>{{cite journal|last1=Cruz|first1=MP|title=Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.|journal=P & T : a peer-reviewed journal for formulary management|date=Aug 2010|volume=35|issue=8|pages=448–51|pmid=20844694|pmc=2935643}}</ref>
| excretion = renal (80%; 50% [range: 40-75%] as unchanged drug)<ref name = DM/><ref name = MSR/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 29110-47-2
| ATC_prefix = C02
| ATC_suffix = AC02
| ATC_supplemental =  
| PubChem = 3519
| IUPHAR_ligand = 522
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01018
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3399
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 30OMY4G3MK
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08031
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 862
<!--Chemical data-->
| C=9 | H=9 | Cl=2 | N=3 | O=1
| molecular_weight = 246.093 g/mol
| smiles = Clc1cccc(Cl)c1CC(=O)\N=C(/N)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = INJOMKTZOLKMBF-UHFFFAOYSA-N
}}
'''Guanfacine''' (trade names '''Estulic''', '''Tenex''', and, in [[extended release]] form, '''Intuniv''') is a [[sympatholytic]] drug  used to treat [[hypertension]] and [[attention deficit hyperactivity disorder]] (ADHD).<ref>{{drugs.com|monograph|guanfacine}}</ref><ref name=UKlabel2017/>  It is a selective [[Alpha-2A adrenergic receptor|α<sub>2A</sub> receptor]] [[agonist]].<ref name=Belkin2015/>

==Medical uses==
Guanfacine is used alone or with stimulants to treat children and teenagers with [[attention deficit hyperactivity disorder]].<ref name="Effects">{{cite journal |vauthors=Kornfield R, Watson S, Higashi A, Dusetzina S, Conti R, Garfield R, Dorsey ER, Huskamp HA, Alexander GC |title=Impact of FDA Advisories on Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder |journal=Psychiatric Services  |volume=64 |issue=4 |date=April 2013 |doi=10.1176/appi.ps.201200147 |pmid=23318985 |pmc=4023684 |pages=339–46 }}</ref><ref>{{cite journal |last1=Zito |first1=Julie M. |first2=Albert T. |last2=Derivan |first3=Christopher J. |last3=Kratochvil |first4=Daniel J. |last4=Safer |first5=Joerg M. |last5=Fegert |first6=Laurence L. |last6=Greenhill |date=15 September 2008 |title=Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring |journal=Child and Adolescent Psychiatry and Mental Health |volume=2 |issue=1 |pmid=18793403 |pmc=2566553 |doi=10.1186/1753-2000-2-24 |url=http://capmh.biomedcentral.com/articles/10.1186/1753-2000-2-24 |pages=24}} {{open access}}</ref> It is also used to treat high blood pressure.<ref name="MSR"/>

==Adverse effects==
Side effects of guanfacine are dose-dependent.<ref name="Jerie">{{cite journal |last=Jerie |first=P. |year=1980 |title=Clinical experience with guanfacine in long-term treatment of hypertension: Part II: adverse reactions to guanfacine |journal=British Journal of Clinical Pharmacology |volume=10 |pmid=6994770 |issue=Suppl 1 |pages=157S–164S |pmc=1430125 |doi=10.1111/j.1365-2125.1980.tb04924.x }}</ref>

Very common (>10% incidence) adverse effects include sleepiness, tiredness, headache, and stomach ache.<ref name=UKlabel2017>{{cite web|title=Intuniv 1 mg, 2 mg, 3 mg, 4 mg prolonged-release tablets - Summary of Product Characteristics|url=https://www.medicines.org.uk/emc/medicine/31294|publisher=UK Electronic Medicines Compendium|language=en|date=June 2017}}</ref>

Common (1-10% incidence) adverse effects include decreased appetite, depressed mood, anxiety, irritability, mood changes, insomnia, nightmares, dizziness, lack of energy, slowed heart beat, low blood pressure, feeling faint when standing quickly, vomiting, nausea, diarrhea, constipation, dry mouth, urinary incontinence, and rashes.<ref name=UKlabel2017/>

Typical side effects such as fatigue, irritability and stomach upset can take a week or two to subside. Increases in dosage can have the same adjustment period.

==Interactions==
Guanfacine availability is significantly affected by the [[CYP3A4]] and [[CYP3A5]] enzymes, and drugs that inhibit or induce those enzymes change the amount of guanfacine in circulation and thus its efficacy and adverse effects, and likewise guanfacine affects those drugs. Because of its affects on the heart, it needs to be used with caution with other drugs that may affect heart; likewise other drugs that may cause sedation.<ref name=UKlabel2017/>

==Pharmacology==
Guanfacine is a highly selective agonist of the [[alpha-2A adrenergic receptor|α<sub>2A</sub> adrenergic receptor]], with negligible affinity for any other receptor.<ref name=PDSP>{{Citation|title=PDSP K<sub>i</sub> Database |work=Psychoactive Drug Screening Program (PDSP) |author1=Roth, BL |author2=Driscol, J |url=http://pdsp.med.unc.edu/pdsp.php |publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health |accessdate=15 November 2013 |date=12 January 2011 |postscript= |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=8 November 2013 |df= }}</ref> However, it may also be a potent [[5-HT2B receptor|5-HT<sub>2B</sub> receptor]] agonist, potentially (theoretically) contributing to [[Valvular heart disease|valvulopathy]].<ref name = AJMP>{{cite journal |doi=10.1124/mol.109.058057 |pmid=19570945 |pmc=2769050 |title=Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine<sub>2B</sub> Receptor Agonists: Implications for Drug Safety Assessment |journal=Molecular Pharmacology |volume=76 |issue=4 |pages=710–22 |year=2009 |last1=Huang |first1=Xi-Ping |last2=Setola |first2=Vincent |last3=Yadav |first3=Prem N. |last4=Allen |first4=John A. |last5=Rogan |first5=Sarah C. |last6=Hanson |first6=Bonnie J. |last7=Revankar |first7=Chetana |last8=Robers |first8=Matt |last9=Doucette |first9=Chris |last10=Roth |first10=Bryan L. }}</ref> 

===Mechanism of action===
Guanfacine works by activating α<sub>2A</sub> adrenoceptors in the [[central nervous system]]. This results in reduced [[peripheral nervous system|peripheral]] sympathetic outflow and thus a reduction in peripheral [[sympathetic tone]], which lowers both [[Systole (medicine)|systolic]] and [[diastolic]] [[blood pressure]].<ref name="VanZwieten">{{cite journal |last=Van Zwieten |first=P. |last2=Thoolen |first2=M. |lastauthoramp=yes |last3=Timmermans |first3=P. |year=1983 |title=The pharmacology of centrally acting antihypertensive drugs |journal=British Journal of Clinical Pharmacology |volume=15 |issue=Suppl 4 |pages=455S–462S |pmc=1427667 |pmid= |doi=10.1111/j.1365-2125.1983.tb00311.x }}</ref> In ADHD, guanfacine works by strengthening regulation of attention and behavior by the [[prefrontal cortex]].<ref name="Arnsten">{{Citation|author=Arnsten AF |title=The use of α2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder |journal=Expert Review of Neurotherapeutics |volume=10 |issue=10 |pages=1595–605 |date=October 2010 |pmid=20925474 |pmc=3143019 |doi=10.1586/ern.10.133 }}</ref> These enhancing effects on prefrontal cortical functions are thought to be due to inhibition of cAMP-mediated signaling, which is effected by the G-proteins that are generally coupled to the post-synaptic α<sub>2A</sub> adrenoceptors that guanfacine stimulates through binding.<ref name="Arnsten"/><ref>{{cite journal |doi=10.1101/lm.298006 |pmid=17101879 |pmc=1783631 |title=α2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals |journal=Learning & Memory |volume=13 |issue=6 |pages=770–6 |year=2006 |last1=Ramos |first1=Brian P. |last2=Stark |first2=David |last3=Verduzco |first3=Luis |last4=van Dyck |first4=Christopher H. |last5=Arnsten |first5=Amy F. T. }}</ref>

===Pharmacokinetics===
Guanfacine has an oral [[bioavailability]] of 80%.  There is no clear evidence of any [[first-pass metabolism]].  [[Elimination half-life]] is 17 hours with the major elimination route being [[renal]].  The principal [[metabolite]] is the 3-hydroxy-derivative, with evidence of moderate [[biotransformation]], and the key intermediate being an [[epoxide]].<ref name="Kiechel">{{cite journal |last=Kiechel |first=J. |year=1980 |title=Pharmacokinetics and metabolism of guanfacine in man: A review |journal=British Journal of Clinical Pharmacology |pmid=6994775 |volume=10 |issue=Suppl 1 |pages=25S–32S |pmc=1430131 |doi=10.1111/j.1365-2125.1980.tb04901.x }}</ref> It is also shown that elimination in patients with impaired renal function does not differ significantly from those with normal renal function.  As such, metabolism by liver is the assumption for those with impaired renal function, as supported by increased frequency of known side effects of orthostatic hypotension and sedation.<ref>{{cite journal |last=Kirch |first=W. |last2=Kohler |first2=H. |lastauthoramp=yes |last3=Braun |first3=W. |year=1980 |title=Elimination of guanfacine in patients with normal and impaired renal function |journal=British Journal of Clinical Pharmacology |pmid=6994776 |volume=10 |issue=Suppl 1 |pages=33S–35S |pmc=1430110 |doi=10.1111/j.1365-2125.1980.tb04902.x }}</ref>

==History==
In 2010, guanfacine was approved by the FDA for the treatment of [[attention deficit hyperactivity disorder]] for people 6–17 years old.<ref name="Effects"/>

Guanfacine is approved and marketed in the United States<ref>{{cite web |title=FDA Approves Intuniv |website=Drugs.com |url=http://www.drugs.com/newdrugs/shire-announces-fda-approval-once-daily-intuniv-guanfacine-extended-release-adhd-children-1599.html |date=September 2009}}</ref> and Europe<ref>{{cite web |title=European Medicines Agency: Intuniv |website=ema.europa.eu |url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003759/human_med_001910.jsp&mid=WC0b01ac058001d124 |date=October 2015}}</ref>

==Research==
Guanfacine has been studied in [[anxiety disorders]] and [[post traumatic stress syndrome]] in children and adults; it has shown little to no efficacy yet caused adverse effects like dry mouth and light-headedness.<ref name=Belkin2015>{{cite journal|last1=Belkin|first1=MR|last2=Schwartz|first2=TL|title=Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder.|journal=Drugs in context|date=2015|volume=4|pages=212286|pmid=26322115|pmc=4544272}}</ref>

Results of studies using guanfacine to treat [[Tourette's]] have been mixed.<ref>{{cite journal|vauthors=Srour M, Lespérance P, Richer F, Chouinard S |title=Psychopharmacology of Tic Disorders|journal=J Can Acad Child Adolesc Psychiatry|date=2008|volume=17|issue=3|pages=150–159|pmc=2527768|pmid=18769586}}</ref>

Guanfacine has been investigated for treatment of withdrawal for [[opioid]]s, [[ethanol]], and [[nicotine]].<ref>{{Citation |last=Sofuogul |first=M. |lastauthoramp=yes |last2=Sewell |first2=A. |year=2009 |title=Norepinephrine and Stimulant Addiction |journal=[[Addiction Biology]] |pmid=18811678 |volume=14 |issue=2 |pmc=2657197 |pages=119–129 |doi=10.1111/j.1369-1600.2008.00138.x }}</ref> Guanfacine has been shown to help reduce stress-induced craving of nicotine in smokers trying to quit, which may involve strengthening of prefrontal cortical self-control.<ref>{{cite journal | last1 = McKee | first1 = SA | last2 = Potenza | first2 = MN | last3 = Kober | first3 = H | last4 = Sofuoglu | first4 = M | last5 = Arnsten | first5 = AF | last6 = Picciotto | first6 = MR | last7 = Weinberger | first7 = AH | last8 = Ashare | first8 = R | last9 = Sinha | first9 = R | date = Mar 2015 | title = A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation | journal = J. Psychopharmacol | volume = 29 | issue = 3| pages = 300–311 | doi = 10.1177/0269881114562091 | pmid = 25516371 | pmc=4376109}}</ref>
[[File:Guanfacine tablets.jpg|250px|thumb|1 mg guanfacine tablets.|alt=Red pills]]

==See also==
* [[Guanabenz]]
*[[Xylazine]]

==References==
{{Reflist|colwidth=30em}}


{{Antihypertensives and diuretics}}
{{ADHD pharmacotherapies}}
{{Adrenergic receptor modulators}}
{{Serotonin receptor modulators}}

[[Category:5-HT2B agonists]]
[[Category:Antihypertensive agents]]
[[Category:Acylguanidines]]
[[Category:Alpha-adrenergic agonists]]
[[Category:Acetamides]]
[[Category:Chloroarenes]]
[[Category:Treatment and management of attention deficit hyperactivity disorder]]